Print PDF

Sheppard Mullin Steers Deal to Create First Global CDMO Focused on Nutraceuticals

Firm Client US Pharma Lab to be Acquired by Biofarma Group

Sheppard Mullin is advising US Pharma Lab, a leading, fast-growing and innovative Contract Development and Manufacturing Organization (“CDMO”) specialized in the custom development, manufacture and distribution of innovative nutraceutical products, in its acquisition by Biofarma Group. Biofarma Group is an Italian and European market leader in the development, manufacturing and packaging of supplements, medical devices, probiotic-based drugs and cosmetics exclusively for third parties.

The highly strategic partnership marks the evolution of Biofarma Group into the first global CDMO solely focused on nutraceuticals with (i) a production footprint in the United States, Europe and China, (ii) strong innovation capabilities on both sides of the Atlantic with expertise in probiotics and other nutraceutical products, and (iii) a highly complementary customer base, focused on pharma clients, CPGs and digitally native brands. The acquisition is expected to close in the third quarter of 2023.

The Sheppard Mullin deal team representing US Pharma Lab is led by partner Ariel Yehezkel and includes special counsel Amanda Ackerman, attorney Patrick Hao and associate Allison Troianos. Tax aspects of the transaction are led by partners Josh McLane and John Crisp, with invaluable assistance from many other specialists.

Click here to read the press release.

Jump to Page

By scrolling this page, clicking a link or continuing to browse our website, you consent to our use of cookies as described in our Cookie and Advertising Policy. If you do not wish to accept cookies from our website, or would like to stop cookies being stored on your device in the future, you can find out more and adjust your preferences here.